Sign in
Taking peoplePhase 2

PRP Exosomes Therapy for Erectile Dysfunction

Key facts

Who runs it
Institute for the Study of Urological Diseases, Greece
Where
Greece1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
30 people, planned
Started
20 Jun 2025
Planned end
May 2026
Type of study
Interventional
Treatments tested
  • PRP-derived exosomes injection
Record updated
15 August 2025

Who can take part

Age
40 years to 70 years
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 30 criteriaShow less

Who can take part

  • Consent to participate
  • Age 40-70 years
  • Sexually active in a stable, heterosexual relationship of more than three months duration
  • Presence of ED for at least 6 months
  • IIEF-ED: 17-25 at visit 2. The IIEF classifies the severity of ED into five categories stratified by score: No ED: 26-30, Mild ED: 22-25, Mild to moderate ED: 17-21, Moderate ED: 11-16 and Severe ED: 6-10
  • Patients will be PDE5i users for at least 6 months and report some/good response to PDE5i in the last month before screening (at visit 1
  • Agree to suspend all ED therapy for the duration of the study
  • Agree to attempt sexual intercourse at least 4 times every 3 weeks for the duration of the study without being under the influence of alcohol or recreational drugs
  • Agree to document the outcome using IIEF questionnaire during every visit and the Sexual Encounter Profile (SEP) diary, as needed (months 1 and 3 post treatment)

Who cannot take part

  • Previous major pelvic surgery or pelvic trauma that could impact EF, such as radical prostatectomy, radical cystectomy, or rectal surgery. 19
  • Patients with previous transurethral resection of the prostate (TURP) surgery without sequelae of iatrogenic ED may be included
  • Previous penile surgery of any kind except circumcision and condyloma removal, such as penile lengthening, penile cancer surgery, penile plication, and grafting
  • Previous history of priapism or penile fracture
  • Previous radiation therapy to the pelvis
  • Current or previous hormone use, other than prescribed testosterone, clomiphene or thyroid medication. Subjects with prior or current use of hormonal treatment for prostate cancer are also excluded
  • Refusal to suspend ED therapy for the duration of the study. Subjects who are using Tadalafil as a treatment for benign prostatic hyperplasia (BPH) will also be excluded
  • Patients who are currently using SSRI or psychotropic medications
  • Peyronie's Disease or penile curvature that negatively influences sexual activity
  • Any untreated medical condition (based on medical history)
  • Patients with generalized polyneuropathy or neurological conditions irrespective of cause, such as severe diabetes, multiple sclerosis, or Parkinson's Disease
  • Any condition or behavior that indicates to the Principal Investigator that the subject is unlikely to be compliant with study procedures and visits
  • History of consistent treatment failure with PDE5 inhibitors for therapy of ED
  • Any history of significant psychiatric diseases, such as bipolar disorder or psychosis, greater than one lifetime episode of major depression, current depression of moderate or greater severity
  • Patients with any hematological disorder
  • Abnormal morning serum testosterone level, defined as a value lower than 300 ng/dL (indicative of untreated hypogonadism) or greater than1197 ng/dL
  • Any health history or laboratory result that indicates to the Principal Investigator that the subject has a significant medical condition and should not participate in the study
  • Partners who are < 18 years of age, who are nursing, who wish to become pregnant during the study period, and who have any gynecologic problems, sexual dysfunction, or major medical conditions that would limit participation in sexual intercourse
  • Psychogenic ED
  • Anatomical or neurological abnormalities in the treatment area
  • Men deemed not healthy enough to participate in sexual activity

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 40 and 70 years old?

This trial is currently available in Greece.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

It will be a Single-arm, single-center, feasibility clinical trial with Primary Objective to investigate the treatment efficacy of PRP-derived exosomes injection in men with mild-moderate vasculogenic ED, as measured by the International Index of Erectile Function (IIEF). Also secondary objectives will be to study the adverse events and safety of the PRP-derived exosomes injection treatment in vasculogenic ED patients Study Centers The study will be carried out at Saint Lucas Hospital, Thessaloniki, Greece. Laboratory tests of all patients will be performed at the hospital's microbiology laboratory. PRP-derived exosomes preparation and application will take place at the Regenerative Clinic.

The group in the trial

  • Study ArmTreatment being tested

    All patients will be regular PDE5I users/responders. After one one-month washout period, ED patients will be screened by the IIEF-EF domain, and 30 eligible patients will be enrolled. subjects will receive three sessions of PRP-derived exosomes injection with 21± 3 days treatment interval.

    Treatment: PRP-derived exosomes injection

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Platelet Rich Plasma - Derived Exosomes Therapy for Erectile Dysfunction: A Feasibility Clinical Trial
Criteria questions
Built from NCT07124871, who can take part
Record updated
15 August 2025